Months after striking SHP2 deal with AbbVie, Jacobio pulls in $174M+ from Hong Kong IPO
The seasoned crew at Jacobio has raised $174.1 million on its HKEX debut, fuelling a pipeline anchored by two AbbVie-partnered allosteric SHP2 inhibitors.
It’s significantly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
